AR087227A1 - CONJUGATED INTERFERON TO WITH POLYETHYLENE GLYCOL - Google Patents

CONJUGATED INTERFERON TO WITH POLYETHYLENE GLYCOL

Info

Publication number
AR087227A1
AR087227A1 ARP110102606A ARP110102606A AR087227A1 AR 087227 A1 AR087227 A1 AR 087227A1 AR P110102606 A ARP110102606 A AR P110102606A AR P110102606 A ARP110102606 A AR P110102606A AR 087227 A1 AR087227 A1 AR 087227A1
Authority
AR
Argentina
Prior art keywords
conjugate
formula
ifn
interferon
peg
Prior art date
Application number
ARP110102606A
Other languages
Spanish (es)
Inventor
Lev Alexandrovich Denisov
Tatyana Veniaminova Chernovskaya
Angelina Vsevolodovna Klenova
Dmitri Velantinovich Morozov
Elena Georgievna Rudenko
Original Assignee
Cjsc Biocad
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45497062&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR087227(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cjsc Biocad filed Critical Cjsc Biocad
Publication of AR087227A1 publication Critical patent/AR087227A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se relaciona con el ámbito de la industria farmacéutica y medicina, particularmente con los PEG-derivados de interferones y se refiere a la creación de un conjugado de interferón con polietilenglicol, funcionalmente activo, altamente depurado, estable, con la actividad del interferón a, inmunogenicidad disminuida, acción biológica prolongada y parámetros farmacocinéticas mejorados de fórmula común (1), donde: n - valores enteros de 227 a 10000 de forma tal que la masa molecular de PEG es de aproximadamente 10000 - 40000 Da; m - valor entero ³ 4; IFN - polipéptido natural o recombinante, que posee actividad IFN-a. También la presente se refiere a medicamentos, que contengan el conjugado de la fórmula (1) presentada, composiciones farmacéuticas, que puedan aplicarse para el tratamiento de enfermedades virales y oncológicas, acompañadas por estado inmuno deficitario primario o secundario, que contenga el conjugado PEG-IFN presentado y complementos auxiliares aceptados. La presente se refiere a la aplicación del conjugado de la fórmula (1) para la obtención de un medicamento que posea una actividad antiviral, antiproliferativa e inmuno modulara, al método de profilaxis y/o tratamiento de enfermedades acompañadas con estado inmuno deficitario primario o secundario, que incluya la introducción de una cantidad terapéuticamente eficiente del conjugado de la fórmula (1), y el contenedor que incluya la composición farmacéutica y el conjunto correspondiente.Reivindicación 1: El conjugado estable de interferón-a PEGilado de fórmula (1), que representa un solo isómero posicional, donde: n - valores enteros de 227 a 10000; m - valor entero ³ 4; Na-H-IFN - interferón-a.It relates to the field of the pharmaceutical and medical industry, particularly with PEG-derivatives of interferons and refers to the creation of an interferon conjugate with polyethylene glycol, functionally active, highly purified, stable, with the activity of interferon a, immunogenicity decreased, prolonged biological action and improved pharmacokinetic parameters of common formula (1), where: n - integer values from 227 to 10,000 so that the molecular mass of PEG is approximately 10,000-40000 Da; m - integer value ³ 4; IFN - natural or recombinant polypeptide, which possesses IFN-a activity. This also refers to medicines, which contain the conjugate of the formula (1) presented, pharmaceutical compositions, which can be applied for the treatment of viral and oncological diseases, accompanied by primary or secondary immuno-deficit status, which contains the PEG-conjugate. IFN presented and auxiliary supplements accepted. This refers to the application of the conjugate of the formula (1) to obtain a medicament that possesses an antiviral, antiproliferative and immuno-modulatory activity, to the method of prophylaxis and / or treatment of diseases accompanied by primary or secondary immune deficit status. , which includes the introduction of a therapeutically efficient amount of the conjugate of the formula (1), and the container that includes the pharmaceutical composition and the corresponding set. Claim 1: The stable PEGylated interferon-a conjugate of formula (1), which represents a single positional isomer, where: n - integer values from 227 to 10,000; m - integer value ³ 4; Na-H-IFN - interferon-a.

ARP110102606A 2010-07-20 2011-07-19 CONJUGATED INTERFERON TO WITH POLYETHYLENE GLYCOL AR087227A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2010129824/10A RU2447083C1 (en) 2010-07-20 2010-07-20 NOVEL FUNCTIONALLY ACTIVE, HIGHLY PURE, STABLE CONJUGATE OF INTERFERON α WITH POLYETHYLENE GLYCOL, REPRESENTED BY ONE PEG- NαH-IFN POSITIONAL ISOMER, WITH IMPROVED IMMUNOGENICITY, WITH PROLONGED BIOLOGICAL ACTION, SUITABLE FOR MEDICAL APPLICATION, AND IMMUNOLOGICAL AGENT BASED THEREON

Publications (1)

Publication Number Publication Date
AR087227A1 true AR087227A1 (en) 2014-03-12

Family

ID=45497062

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110102606A AR087227A1 (en) 2010-07-20 2011-07-19 CONJUGATED INTERFERON TO WITH POLYETHYLENE GLYCOL

Country Status (20)

Country Link
KR (1) KR101586372B1 (en)
CN (1) CN102617736B (en)
AR (1) AR087227A1 (en)
BR (1) BRPI1101565A2 (en)
CO (1) CO6680611A2 (en)
CR (1) CR20130021A (en)
CU (1) CU24193B1 (en)
DO (1) DOP2013000002A (en)
EA (1) EA020257B1 (en)
EC (1) ECSP13012398A (en)
HK (1) HK1170504A1 (en)
MX (1) MX2011007458A (en)
MY (1) MY168784A (en)
NI (1) NI201300008A (en)
PE (1) PE20131034A1 (en)
RU (1) RU2447083C1 (en)
SG (1) SG187117A1 (en)
UA (1) UA99766C2 (en)
UY (1) UY33525A (en)
WO (1) WO2012011836A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2515913C1 (en) * 2013-03-22 2014-05-20 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт генетики и селекции промышленных микроорганизмов" (ФГУП "ГосНИИгенетика") HYBRID PROTEIN HAVING PROLONGED ACTION, BASED ON RECOMBINANT HUMAN INTERFERON ALPHA-2 (VARIANTS), METHOD OF ITS PRODUCTION AND STRAIN OF Saccharomyces cerevisiae FOR IMPLEMENTING THIS METHOD (VERSIONS)
EA021643B1 (en) * 2013-03-28 2015-07-30 Илья Александрович МАРКОВ Monopegylated interferon-alpha of linear structure and a pharmaceutical composition for preparing a medicament having interferon-alpha activity
EA021610B1 (en) * 2013-03-28 2015-07-30 Илья Александрович МАРКОВ Liquid antiviral formulation
CN103463623B (en) * 2013-09-03 2015-09-09 长春海伯尔生物技术有限责任公司 A kind of Peg-IFN alpha-2b injection and preparation method thereof
RU2554761C1 (en) * 2014-05-13 2015-06-27 Закрытое акционерное общество "Сибирский центр фармакологии и биотехнологии" Anti-enteroviral and immunostimulating agent
RU2572800C1 (en) * 2014-09-22 2016-01-20 Закрытое Акционерное Общество "Биокад" New formulation containing polyethylene glycol (peg) conjugated interferon alpha-2beta characterised by less painful administration
EA029498B1 (en) * 2015-11-24 2018-04-30 Учреждение Белорусского государственного университета "Научно-исследовательский институт физико-химических проблем" (НИИ ФХП БГУ) ANTI-TUMOUR DRUG BASED ON RECOMBINANT INTERFERON ALPHA-2b IN THE FORM OF MICROPARTICLES FOR PARENTERAL ADMINISTRATION
RU2678332C1 (en) 2017-09-08 2019-01-28 Общество с ограниченной ответственностью "Саентифик Фьючер Менеджмент" (ООО "СФМ") Pegylated interferon lambda with high bioaccessability in oral use and method for production thereof
AU2021258734A1 (en) * 2020-04-20 2023-01-05 Altum Pharmaceuticals Inc. Recombinant interferon
CN114392237B (en) * 2021-12-28 2024-02-02 上海允英生物医药科技有限公司 Freeze-dried virus preparation and preparation method thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US20030053982A1 (en) * 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
JP2758154B2 (en) * 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー Liquid preparations containing interferon
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
RS20050202A (en) * 2002-09-09 2007-08-03 Nektar Therapeuticals Al.Corporation, Water-soluble polymer alkanals
RU2311930C2 (en) * 2004-04-30 2007-12-10 Закрытое акционерное общество "ВЕРОФАРМ" Pagylated interferon against viral infection
CA2572751A1 (en) * 2004-06-30 2006-01-12 Egen Corporation Pegylated interferon alpha-1b
US7872082B2 (en) * 2005-07-19 2011-01-18 Nektar Therapeutics Method for preparing polymer maleimides
JP2009541333A (en) * 2006-06-23 2009-11-26 クインテセンス バイオサイエンシーズ インコーポレーティッド Modified ribonuclease
CN101491682A (en) * 2008-04-30 2009-07-29 北京凯正生物工程发展有限责任公司 PEG-IFN omega conjugate and preparation technique thereof
CN101591387A (en) * 2008-05-28 2009-12-02 中国人民解放军军事医学科学院微生物流行病研究所 PEG-IFN omega conjugate
CN101514229B (en) * 2009-04-03 2012-05-09 海南四环心脑血管药物研究院有限公司 Human interferon alpha derivative and polyethylene glycol modified substance thereof

Also Published As

Publication number Publication date
CU20130013A7 (en) 2013-04-19
EA020257B1 (en) 2014-09-30
KR101586372B1 (en) 2016-01-18
HK1170504A1 (en) 2013-03-01
MX2011007458A (en) 2012-01-19
KR20130056885A (en) 2013-05-30
BRPI1101565A2 (en) 2012-12-04
ECSP13012398A (en) 2013-05-31
SG187117A1 (en) 2013-02-28
CN102617736B (en) 2015-11-25
CN102617736A (en) 2012-08-01
CR20130021A (en) 2013-02-20
WO2012011836A1 (en) 2012-01-26
RU2010129824A (en) 2012-01-27
DOP2013000002A (en) 2013-09-15
PE20131034A1 (en) 2013-09-27
CO6680611A2 (en) 2013-05-31
NI201300008A (en) 2014-05-26
UY33525A (en) 2012-02-29
CU24193B1 (en) 2016-09-30
MY168784A (en) 2018-12-04
RU2447083C1 (en) 2012-04-10
UA99766C2 (en) 2012-09-25
EA201100809A1 (en) 2012-01-30

Similar Documents

Publication Publication Date Title
AR087227A1 (en) CONJUGATED INTERFERON TO WITH POLYETHYLENE GLYCOL
DOP2011000343A (en) PIRIDINE TIENO DERIVATIVES [2,3-B] AS VIRAL REPLICATION INHIBITORS
EA201290395A1 (en) IMMUNOMODULATING POLYPEPTIDES OBTAINED FROM IL-2 AND THEIR USE FOR THE TREATMENT OF CANCER AND CHRONIC INFECTIONS
WO2013002580A3 (en) Exendin-4 analogue pegylated with polyethylene glycol or derivative thereof, preparation method thereof, and pharmaceutical composition for preventing or treating diabetes, containing same as active ingredient
MD4430B1 (en) Compositions and methods for treating hepatitis C virus
MX2010002557A (en) Polyethylene glycol modified interferon alpha 2b and preparation method and applicatioins thereof.
WO2009043458A3 (en) Use of oxytocin to treat many diseases
WO2009033770A3 (en) Calcitonin c-terminal flanking peptide for use as a therapeutic agent
WO2009046832A3 (en) Short peptides used in medicine
EA200800467A1 (en) APPLICATION OF COMPLEX ETHERS OF HYDROXYBENZOIC ACID AND ANALOGUES FOR OBTAINING MEDICINES FOR THE PREVENTION AND TREATMENT OF VIRAL INFECTION
JP2013541521A5 (en)
RU2013148779A (en) TREATMENT OF HEPATITIS VIRUS INFECTION IN SEPARATELY OR IN COMBINATION WITH DELTA HEPATITIS VIRUS AND LIVER-LIVING DISEASES OF THE LIVER
WO2014006502A8 (en) Protozoan variant-specific surface proteins (vsp) as carriers for oral drug delivery
CL2021003474A1 (en) Pharmaceutical product for enzyme therapy for the treatment of homocystinuria
BR112022010574A2 (en) PHARMACEUTICAL COMPOSITIONS INCLUDING CABOTEGRAVIR
AR117715A1 (en) HYPERGLYCOSILATED INTERFERON WITH REDUCED IMMUNOGENICITY
JP2013542196A5 (en)
MD3121F1 (en) Method of viral hepatitis B prophylaxis
WO2014014389A3 (en) Composition in gel form for the prophylaxis and treatment of periodontal diseases
RU2014116988A (en) ALISPORIVIR FOR TREATING INFECTIONS CAUSED BY HEPATITIS C VIRUS
MX2024008242A (en) Compositions containing fexofenadine.
RU2012109938A (en) METHOD FOR TREATING VIRAL HEPATITIS C
RU2014140049A (en) MOLECULE interferon-β-1a HUMAN pegylated, possess antiviral, immunomodulating and antiproliferative activity, with improved stability, reduced immunogenicity, improved pharmacokinetic and pharmacodynamic parameters suitable for medical applications, and immunobiological BEING ON ITS BASIS
Mandorfer Boceprevir/peginterferon-alfa-2a/ribavirin
AR105794A1 (en) CHARACTERIZED PHARMACEUTICAL COMPOSITION BECAUSE IT INCLUDES AN ANTIBODY, A MEDICINAL PRODUCT THAT INCLUDES IT AND ITS USE IN THERAPY

Legal Events

Date Code Title Description
FB Suspension of granting procedure